Our GL-332 program is a novel, once-daily, siderophore cephalosporin antibiotic series, being developed to replace older second and third generation cephalosporins such as once-daily cephalexin, ceftazidime, and cefipime for the empiric treatment of bacterial infections. GL-332 is actively transported into Gram-negative cells by exploiting iron uptake systems that use low molecular weight iron-binding molecules known as siderophores to transport iron into the cells. This "Trojan Horse" strategy facilitates uptake of GL-332 into the bacterial periplasmic space in high concentrations where they bind to its penicillin-binding protein targets and disrupt cell wall synthesis, leading to bacterial cell death. This increased transportation into bacterial cells potentiates activity against Gram-negative bacteria, including activity against common and resistant Gram negative bacteria. IND-enabling studies will be completed for GL-332 in 2019 and clinical studies will be initiated in 2020.